1. Home
  2. NFE vs CABA Comparison

NFE vs CABA Comparison

Compare NFE & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Fortress Energy Inc.

NFE

New Fortress Energy Inc.

HOLD

Current Price

$0.59

Market Cap

324.4M

Sector

Utilities

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.76

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFE
CABA
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.4M
319.6M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
NFE
CABA
Price
$0.59
$2.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$7.70
$13.43
AVG Volume (30 Days)
20.0M
1.7M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
$2,364,860,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$89.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.99
52 Week High
$7.92
$3.78

Technical Indicators

Market Signals
Indicator
NFE
CABA
Relative Strength Index (RSI) 25.05 45.35
Support Level N/A $2.11
Resistance Level $1.38 $3.34
Average True Range (ATR) 0.13 0.23
MACD -0.03 -0.05
Stochastic Oscillator 3.72 36.15

Price Performance

Historical Comparison
NFE
CABA

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: